Vodobatinib - Sun Pharma Advanced Research Company
Alternative Names: K-0706; SCO-088; SUN K706; SUN-K0706Latest Information Update: 02 Aug 2024
At a glance
- Originator Sun Pharma Advanced Research Company
- Class Antidementias; Antineoplastics; Antiparkinsonians; Benzoic acids; Chlorinated hydrocarbons; Quinolines; Small molecules
- Mechanism of Action Bcr-Abl tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Lewy body disease; Parkinson's disease
- Phase I/II Chronic myeloid leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 06 Jun 2024 Sun Pharma terminates Phase-II clinical trials in Parkinson's disease (In the elderly) in USA (PO) due to study outcomes (NCT03655236)
- 25 Jul 2022 Vodobatinib is still in phase II trials for Lewy body disease (In the elderly, Treatment-experienced, In adults) in USA (PO) (NCT03996460)
- 05 Dec 2020 Interim adverse events and efficacy data from a phase I/II trial in Chronic Myeloid Leukemia presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology (ASH-2020)